#### Species-specific bacterial detector for fast pathogen diagnosis of severe pneumonia 1

#### patients in the intensive care unit 2

- Yan Wang<sup>1</sup>#, Xiaohui Liang<sup>2</sup>#, Yuqian Jiang<sup>2</sup>, Danjiang Dong<sup>1</sup>, Cong Zhang<sup>2</sup>, 3
- Tiangiang Song<sup>2</sup>, Ming Chen<sup>1</sup>, Yong You<sup>1</sup>, Han Liu<sup>3</sup>, Min Ge<sup>4</sup>, Haibin Dai<sup>5</sup>, Fengchan 4
- Xi<sup>6</sup>, Wanqing Zhou<sup>7</sup>, Jian-Qun Chen<sup>2</sup>, Qiang Wang<sup>2</sup>\*, Qihan Chen<sup>2,8</sup>\*, Wenkui Yu<sup>1,8</sup>\* 5
- 6

- Hospital of Nanjing University Medical School, Nanjing, Jiangsu 21008, China. 8
- 9 2 The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences,
- Nanjing University, Nanjing, Jiangsu 210023, China. 10
- 3 Department of Critical Care Medicine, Nanjing First Hospital, Nanjing Medical 11
- 12 University, Nanjing, Jiangsu 210006, China.
- 4 Department of Cardiothoracic Surgery Intensive Care Unit, Nanjing Drum Tower 13
- Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 14 Jiangsu 210008, China. 15
- 5 Department of Neurosurgery Intensive Care Unit, Nanjing Drum Tower Hospital, The 16
- 17 Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008,
- China. 18
- 6 Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of 19 Nanjing University, Nanjing, Jiangsu 210002, China. 20
- 7 Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated 21
- Hospital of Nanjing University Medical School, Nanjing University, Nanjing 210008, 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 China.
- 24 8 Medical School of Nanjing University, Nanjing, Jiangsu 210093, China.
- 25 #These authors share first author
- 26 \*Corresponding author
- 27 Corresponding Author:
- 28 Wenkui Yu, Ph.D., M.D.
- 29 Department of Critical Care Medicine, Nanjing Drum Tower Hospital
- 30 Nanjing, Jiangsu 21008, China
- 31 Phone: +86 13701582986
- 32 <u>yudrnj2@163.com</u>
- 33
- 34 Qihan Chen, Ph.D.
- 35 School of Life Sciences, Nanjing University
- 36 Nanjing, Jiangsu 210023, China
- 37 Phone: +86 13236592587
- 38 <u>chenqihan@nju.edu.cn</u>
- 39
- 40 Qiang Wang, Ph.D.
- 41 School of Life Sciences, Nanjing University
- 42 Nanjing, Jiangsu 210023, China
- 43 Phone: +86 13382014346
- 44 <u>wangq@nju.edu.cn</u>.

#### 45 Abstract

Rapid diagnosis of pathogens is the cornerstone of appropriate therapy and is also a 46 47 great challenge to be overcome. Although NGS and some other PCR-based pathogen detection methods were applied to improve the speed and accuracy of clinical diagnosis, 48 it was still a long way from the clinical needs of rapid and accurate diagnostic therapy 49 in the intensive care unit (ICU). In this study, we aimed at developing a new rapid 50 diagnostic tool, Species-Specific Bacterial Detector (SSBD), to evaluate the existence 51 and quantification of 10 most usual pathogenic bacteria in ICU in 4 hours. Briefly, the 52 53 species-specific genome fragments of each bacterium were identified by our algorithm using 1791 microbe genomes from 232 species and then used to combine with 54 CRISPR/Cas12 to establish diagnosis tools. Based on the tests of 77 samples, SSBD 55 56 demonstrated 100% sensitivity and 87% specificity compared with conventional culture test (CCT). Later on, an interventional random-grouped study was applied to 57 evaluate the clinical benefits of SSBD. Briefly, SSBD demonstrated more accurate and 58 59 faster diagnosis results and led to earlier antibiotics adjustment than CCT. Based on the results acquired by SSBD, cultivation results could deviate from the real pathogenic 60 situation with polymicrobial infections. In addition, nosocomial infections were found 61 widely in ICU, which should deserve more attention. 62

63

Keywords: Diagnosis, Pathogen, Severe pneumonia, Intensive care unit, Antimicrobial
 therapy

66

### 67 **1. Introduction**

Sepsis is associated with high morbidity and mortality [1]. Adequate antibiotic therapy in time could decrease mortality and reduce the length of stay in ICU for patients with sepsis or septic shock [2-5]. As reported in the previous study, the mortality rate of patients increased approximately 7.6% for every hour delayed [3]. Therefore, rapid diagnosis of pathogenic microorganisms is crucial for shortening the time of empirical antibiotic therapy and improving the prognosis of patients with sepsis.

Conventional culture test (CCT) is the most commonly used and golden standard 74 75 identification method of pathogenic microorganisms in most countries. However, it showed two critical limitations: long time-consuming (2 to 5 days) and low sensitivity 76 (30-50%), which limited the application of this method in the ICU [6, 7]. To overcome 77 78 this bottleneck, several new tools were developed and showed significant improvement in time consumption and accuracy. Recently, next-generation sequencing (NGS) 79 technology was applied to acquire the entire information of microorganisms and 80 81 demonstrated great ability in diagnosing rare pathogens. However, the whole process still needs at least 2 days for the full diagnostic report with high cost [8, 9]. On the other 82 hand, NGS provided too much information about microorganisms but only semi-83 quantification of pathogens, which was hard for most clinical doctors to extract the most 84 important information to determine antibiotic usage. Other new emerging detection 85 techniques designed by BioFire and Curetis are much superior in detection time than 86 these above. However, its original principle was based on nucleotide diversity of 87 conserved genes among species, which could not satisfy the application in the ICU due 88

to potential false-positive results [10-12]. Therefore, a unique diagnosis tool aimed at faster and more accurate pathogen identification in the ICU was still a great challenge. In this study, we aimed to design a simple and convenient diagnosis tool for sepsis patients in the ICU, which covered the most common pathogenic bacteria and completed the detection process in the shortest possible time with low cost and minimum instrument requirements. A clinical trial with two stages was applied to evaluate the accuracy of the tool and the clinical benefits.

96

#### 97 2. Materials and Methods

### 98 2.1. Study design

99 The full study design was shown in Fig 1. In the discovery stage, we screened species

100 specific DNA-tags of 10 epidemic pathogenic bacteria in the ICU. In the training stage,

101 we optimized reaction conditions and sample preparation process, including detection

102 concentration limitation, DNA purification, and incubation time of the CRISPR/Cas12a

103 reaction. The finalized experiment operating procedure of SSBD was used in the

104 subsequent stages (detailed protocol was shown in Supplementary Materials).

105 In validation stage I, 77 specimens of bronchoalveolar lavage fluid (BALF) directly

acquired from patients in ICU were finally detected by SSBD to confirm the specificity

107 and sensitivity of SSBD compared to CCT results. Some of the samples were sent to

108 NGS technology, providing additional references.

109 After the stability and accuracy of SSBD were thoroughly evaluated, the validation 110 stage II, a preliminary clinical intervention experiment, was launched to verify the

111 clinical application of the SSBD.

#### 112 **2.2. Ethics Approval**

- 113 We acquired the ethics approval (2019-197-01) from the ethics committee of Nanjing
- 114 Drum Tower Hospital Affiliated to Nanjing University Medical School in July 2019,

registered and posted the complete research protocol, informed consent, subject materials, case report form, researcher manual, the introduction of main researchers and other information in Chinese. Later on, this study was registered in English at ClinicalTrilas.gov (NCT04178382) in November 2019.

119 **2.3. Screening species-specific DNA tags** 

We designed a process to find the species-specific DNA tags according to the basic 120 principle, intraspecies-conserved and interspecies-specific sequences (illustrated in Fig 121 122 2A). 1791 high-quality genomes of 232 microorganism species from the public databases were included in the screening process. To accelerate the screening process, 123 we developed a linear comparison algorithm instead of comparing every two genomes, 124 which could save more than 90% of calculation time cost (S1 Fig). 10 species of 125 bacteria were selected as targets for subsequent detecting process, including 126 Acinetobacter baumannii (A. baumannii), Escherichia coli (E. coli), Klebsiella 127 (*K*. pneumoniae), Pseudomonas 128 pneumoniae aeruginosa (*P*. aeruginosa), Stenotrophomonas maltophilia (S. maltophilia), Staphylococcus aureus (S. aureus), 129 Staphylococcus epidermidis (S. epidermidis), Staphylococcus capitis (S. capitis), 130 Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium). Then we 131 designed different DNA primers targeting selected species-specific DNA tags from each 132

#### 133 species (S1 and S2 Table).

To evaluate our primers' specificity in identifying species, we chose S. aureus and S. 134 epidermidis from the same genus as our cross-validated target species. We extracted 135 DNA sequences of the S. aureus and the S. epidermidis amplified by primers used in 136 137 FilmArray Pneumonia Panel developed by BioFire and in our protocol, which were acquired from NCBI Reference Prokaryotic Representative genomes. We then aligned 138 S. aureus-specific DNA sequences with the representative genome of S. epidermidis 139 using blast to search the most similar DNA sequences. In the FilmArray Pneumonia 140 141 Panel, DNA amplified sequences from the S. aureus and the S. epidermidis were aligned to each other (two different gene regions, rpoB and gyrB, were used to separate two 142 species). 143

#### 144 **2.4. Patients**

Patients admitted to ICUs and diagnosed with severe pneumonia were recruited from 145 Aug 27, 2019. The recruit criteria for patients were: (1) age  $\geq$  18 years; (2) had artificial 146 147 airway and expected to retain for more than 48 hours; (3) clinically diagnosed as pneumonia, and the microbiology of etiology was unclear; (4) signed informed consent; 148 (5) the expected length of staying in ICU was more than 3 days. According to previous 149 mortality acquired from the adequate anti-infective group, the sample size calculation 150 (two-group rate) for patients was done, and a sample size of 73 patients in each group 151 was needed. 152

#### 153 **2.5. Clinical outcomes**

154 BALFs were obtained from all the patients from 2 groups on day 1, day 3-5, and day 7-

155 10 after recruitment and were sent directly to the hospital diagnostic microbiology 156 laboratory for CCT and susceptibility testing. BALFs from patients of the experiment 157 group were also sent for SSBD tests immediately after sampling. Other clinical records 158 included blood routine tests, CRP and PCT examinations.

All enrolled patients received primary empirical antibiotic therapy. Once the SSBD 159 results of the patients in the experiment group were obtained, the decisions about 160 whether antibiotics were adjusted or not were made by two senior doctors according to 161 the SSBD results and other clinical information. While in the control group, adjustment 162 163 depended on conventional culture results and clinical data. Patient demographics and other vital clinical parameters were recorded. Acute Physiology and Chronic Health 164 Evaluation II (APACHE II) scores and Sequential Organ Failure Assessment (SOFA) 165 166 scores were calculated and recorded for patients on days 1, 3, 7, 10 and 14 to assess their disease severity and organ function. 167

#### 168 **2.6. Statistical analysis**

169 The number of improved patients on different clinical indicators of different days was 170 calculated and tested by Fisher's exact test. APACHE II scores and SOFA scores were 171 tested as a series by two-way ANOVA. Different clinical outcomes and TTAT were 172 tested by the Mann-Whitney test.

173 **2.6. Funding support** 

This study was funded by National Natural Science Foundation of China. The National
Key Scientific Instrument and Equipment Development Project. Project number:
81927808.

177

#### 178 **3. Results**

### 179 **3.1.** The identification of species-specific DNA fragments

The first step to identify pathogenic bacteria was to figure out the specific genome 180 information of each species. Unlike viruses or animals, bacteria were quite similar 181 between close-related species but sometimes quite different among different strains of 182 one species due to fast evolution and horizontal gene transfer [13-15]. Therefore, the 183 widely-used method to identify bacteria with conserved genes may not be a good choice 184 185 [16, 17]. We developed an innovative algorithm and designed a workflow to figure out the best DNA tag for each species for diagnostic application based on 1791 microbe 186 genomes from 232 species (Fig 2A). The details could be found in the Supplementary 187 188 Materials.

We started from 10 common bacteria contributing to sepsis infection as the initial 189 panel according to local epidemic data from ICU of Drum Tower hospital and previous 190 191 studies about pathogens in ICU (S2 Fig) [18, 19]. To our surprise, bacteria-specific DNA sequences showed a random distribution and turned out to be only 0.3%-4.1% in 192 the whole genomes of 10 bacteria (Fig 2B and 2C). Considering the application 193 scenario of ICU with only basic instruments, PCR+CRISPR/Cas12a system was chosen 194 for the following detection. Based on the identified species-specific DNA fragments, 195 related primers and crRNAs (CRISPR RNA) were designed according to each species 196 (S1 and S2 Table). 197

#### 198 **3.2.** The establishment of species-specific bacteria detection tool

Briefly, CRISPR/Cas12a with designed crRNA could be activated by its target, which could be told by whether the reporter probe was cleaved and demonstrated signal as previously reported [20].

To optimize the working conditions of the detection tool in ICU, multiple 202 203 experiments were applied to optimize the sample preparation and detection process. 204 With the gradient concentration of DNA templates, we confirmed that the lowest detection limit was 10<sup>-15</sup> M with PCR amplification and 10<sup>-8</sup>M without amplification 205 step (Fig 3B), which was consistent with previous studies [21]. In addition, 30 minutes' 206 207 incubation of CRISPR/Cas12a with PCR products was enough to demonstrate signals (Fig 3B). An additional purification step right after PCR amplification appeared 208 unnecessary to acquire the positive result but helpful for weaker signal (S3A Fig). In 209 210 addition, the comparison of CRISPR/Cas incubation duration confirmed that fluorescence value showed a significant difference from 5 minutes and reached its 211 maximum after 30 minutes compared to the negative control (S3B Fig). 212

213 To confirm the primary behavior of SSBD, two clinical strains separated from different patients for each of 10 selected bacteria species were collected and tested by 214 SSBD as the positive control, which showed clear positive results (S3C Fig). To further 215 confirm the specificity of SSBD, each bacteria strain was tested by 10 SSBD test panels 216 targeting different bacteria. Compared to negative control, only SSBD targeting the 217 tested bacteria showed a positive result, which confirmed its high specificity (Fig 3C). 218 Putting these results together, a standard operating procedure was finally established 219 for the following validation stages (Fig 3A), which was capable of providing the 220

information about the ten most common pathogenic bacteria in ICU. Since this method

222 was a quite fast and <u>species-specific bacteria detection tool</u>, we named it SSBD.

223 **3.3. The accuracy and clinical benefits of SSBD** 

We started our study with validation stage I, which was a non-intervention study with 224 77 samples of BALF extracted from patients. Samples were detected both by SSBD 225 and CCT, and the results were compared (raw detection results were shown in **S3 Table**). 226 Generally, 5 of 10 selected bacteria were detected by both tests, including A. baumannii, 227 K. pneumoniae, P. aeruginosa, S. aureus and S. maltophilia. SSBD could detect those 228 229 5 bacteria separately with 100% sensitivity and over 87% specificity, which were calculated by the results of CCT as golden standard (Fig 4A). The other 5 bacteria were 230 detected by SSBD but not CCT, including E. coli, S. epidermidis, S. capitis, E. faecalis 231 232 and E. faecium. To further evaluate the results, 11 samples among all 77 samples were collected randomly and sent for NGS detection, which confirmed that SSBD and NGS 233 demonstrated quite high similarities in results (Fig 4A). 234 235 Based on these accurate results, we started the validation stage II, which was an

intervention study aiming to evaluate the clinical benefits of SSBD compared to the
current diagnosis and treatment strategy in ICU. Although the study was paused due to
the outbreak of SARS-CoV2, 22 patients were recruited into the experiment group and
24 patients into the control group. The baseline characteristics had no significant
difference except ages (S5 Table).

We finally got 57 BALF results tested by SSBD, which included 43 results that also had CCT results among them in the experiment group. While in the control group, we

| 243 | got 63 samples tested only by CCT. In the experiment group, 47 samples were positive     |
|-----|--|
| 244 | among 57 samples tested by SSBD, while 28 samples were positive among 43 samples         |
| 245 | tested by CCT (raw detection results were shown in S4 Table). In the control group, 41   |
| 246 | samples showed positive among 63 samples. It was shown that SSBD could detect each       |
| 247 | bacterium with similar high sensitivity and specificity in validation stage II (Fig 4B). |
| 248 | Consistent with the local epidemic data, the most frequent occurrence was A. baumannii   |
| 249 | (Fig 4B). 12 of the 57 samples were also sent for the NGS technology, and the SSBD       |
| 250 | also showed high consistency between those two methods compared to CCT (Fig 4B).         |
| 251 | To explore clinical benefits with the help of SSBD, effective antibiotic coverage rate,  |
| 252 | APACHE II scores and SOFA scores were calculated and compared to evaluate the            |
| 253 | rationalization of antibiotic therapy and patients' disease severity and organ function  |
| 254 | status in the two groups (Fig 4C-4E). Effective antibiotic coverage rates for each test  |
| 255 | were significantly higher in the experimental group than those in the control group in   |
| 256 | three tests (Fig 4C). The definition of antibiotic coverage and the original calculation |
| 257 | results were shown in S4A-B Fig. APACHE II scores were significantly lower in the        |
| 258 | experimental group than those in the control group after day 1 (p=0.0035, two-way        |
| 259 | ANOVA); the separation between two groups of patients increased progressively until      |
| 260 | day 14 (Fig 4D). SOFA scores showed no difference between the groups (p=0.8918,          |
| 261 | two-way ANOVA) (Fig 4E). Other clinical outcomes showed no significant difference        |
| 262 | in both groups, such as time of ventilation, shock, 28-day mortality and the numbers of  |
| 263 | antibiotic-associated diarrhea (S6 Table).   |

264 **3.4.** Polymicrobial infection and nosocomial events observed by SSBD

Based on the previous studies, CCT had defects in the evaluation of polymicrobial 265 infection events due to the limitations of its technology [22]. Therefore, we tried to 266 267 evaluate whether SSBD demonstrated better performance with polymicrobial infection. Here, we defined situations of infection with more than one pathogenic microorganism 268 as polymicrobial infection events to assess the performance based on the results of both 269 methods. From the results, the detection rate of polymicrobial infection events by SSBD 270 was 41.8% (55/134) in two validation stages, which was significantly higher than 11.7% 271 (14/120) of CCT (Fig 5A). To confirmed the reliability of the extra detected 272 polymicrobial infection events by SSBD, 6 samples were sent for NGS, which 273 demonstrated the same results as SSBD (Fig 5B). 274

Since both SSBD and NGS were based on target DNA, we wanted to confirm if some 275 276 polymicrobial infection events were "false positive" and caused by dead bacteria. Here, we showed patient B19 as an example, who received three times tests at day 1, 3 and 7 277 by both CCT and SSBD. Based on the results, S. maltophilia was detected as level II in 278 test1 with SSBD but not CCT. Later on, S. maltophilia was detected by CCT in test2 as 279 well with few days' development from level II to level III based on result of SSBD, 280 which means SSBD discovered the true polymicrobial infection event earlier than CCT 281 (Fig 5C). From the aspect of pathogen species participated in polymicrobial infection 282 events, both methods demonstrated similar results with A. baumannii, S. maltophilia, P. 283 aeruginosa, K. pneumoniae and S. aureus in top 5 (Fig 5D), which were consistent with 284 the frequency of pathogens in ICU [18]. 285

Hospital infections, also known as nosocomial infections, are an important factor in

the incidence rate and mortality of ICU patients with severe pneumonia [23]. Since 287 CCT has a long delay in clinical feedback of pathogenic results, there is no effective 288 289 monitoring method in clinical practice. Here, we tried to evaluate nosocomial infections based on the test results. We defined a case as a nosocomial infection event if a 290 pathogenic bacterium was newly detected in the current time point but not before. For 291 example, B17 (K. pneumoniae at test 2, E. faecalis at test 3) and B19 (S. maltophilia at 292 test 2, K. pneumoniae at test 3) patients were discovered as nosocomial infection cases 293 for SSBD and CCT (Fig 5E and 5F). Based on the results of SSBD, 47.6% (10/21) of 294 295 patients had nosocomial infections at the test 2, and 28.6% (4/14) of patients had nosocomial infections at the test 3. Similarly, 40% (4/10) of patients were identified as 296 nosocomial infections by CCT at test 2, and 27.3% (3/11) of patients were identified as 297 nosocomial infections at test 3 (Fig 5G). 298

299

#### 300 4. Discussion

In this study, we developed a rapid bacteria detection technique based on 301 CRISPR/Cas12a using species-specific DNA tags and detected common bacteria taken 302 from pneumonia in 4 hours with 100% sensitivity and over 87% specificity in the 303 validation stage I. Currently, there are already some market-oriented detection 304 technologies for pneumonia patients, such as FilmArray Pneumonia Panel by BioFire 305 and Curetis Unyvero system, which also could detect microorganisms in several hours 306 [12]. Sequences used by FilmArray Pneumonia Panel from two gene regions had highly 307 similar DNA sequences in the S. epidermidis representative genome (E-value=5e-40, 308

rpoB; E-value=8e-39, gyrB), which could interfere with pathogen identification 309 between species from the same genus. It was ideal for early and rapid screening of 310 311 infectious diseases but was not applicable in the ICU, considering the complexity and urgency of infection events within the ICU. We have adopted a completely different 312 strategy from the existing methods, getting specific gene regions from species for 313 314 further test using our developed bioinformatics workflow and algorithm. It was shown that our sequences used for S. aureus diagnosis had no similar fragments in S. 315 epidermidis, which avoided distinguishing different species by gene diversity. It was 316 317 likely to get the species-specific DNA tags from such amount genomes when aligned bacterial genomes with each other but consuming computational cost. We optimized 318 calculation processes by rescheduling steps and then made it possible for us to acquire 319 320 species-specific DNA regions after shortening time to a range bearable.

NGS technology is useful in species identification and also shows its advantages in 321 clinical diagnosis. It is valuable to detect uncommon pathogens because of its unique 322 323 capability in detecting multiple agents across the full microbial spectrum contributing to disease and has already been developed as a new detection platform [9]. However, 324 in the majority of cases of common pathogens, redundant microorganism results were 325 probably unhelpful to the anti-infection regimen. In addition, the high cost and 326 relatively long turnaround time prevent its widespread application, especially in the 327 ICU circumstance. Therefore, our SSBD method seemed more advantageous in time-328 329 consuming and information effectiveness than other mentioned methods, especially when we could quantify bacterial load based on fluorescence intensity for better 330

antibiotic therapy strategy. CRISPR/Cas12a and qPCR are both quantitative methods,
but CRISPR/Cas12a shows its robustness and lower equipment requirement, which
satisfied our needs for most of the ICU. There are still several challenges in
implementing POCT in developing countries, especially the qPCR/POCT system,
which will be an alternative.

The results of SSBD demonstrated high sensitivity and specificity. However, we 336 discovered several "false positive" results compared to CCT, which might be caused by 337 two reasons: 1) The low bacterial load of the patient sample was probably not enough 338 339 or needed much longer time than expected to be cultivated. SSBD provided a lower threshold of detection (10<sup>-15</sup> M) than CCT, which could detect pathogens that even 340 existed in trace amounts which unable to be cultivated. In our study, the fluorescence 341 intensity obtained from SSBD was divided into three intervals (level I: 10<sup>-15</sup>-10<sup>-14</sup> M, 342 level II: 10<sup>-14</sup> M-10<sup>-13</sup> M, level III: over 10<sup>-13</sup> M), representing the different strengths of 343 bacteria (roughly equivalent to bacteria amounts according to our lowest detection 344 thresholds, dividing details in Supplementary Method SSBD diagnostic report and S4A 345 Fig). All false-positive results were calculated on the count of species and strengths, 346 mostly belonging to the level I or II (S5 Fig). Considering most of those false positive 347 samples were also validated by NGS technology, it suggested that some pathogens 348 might be missed in the CCT results. 2) Cultivation could fail in detecting pathogens 349 that failed in competitive growth environments. It was interesting to see that many 350 patients were infected by more than one pathogen, which might cause potential 351 competition between different pathogens in CCT process (S7 Table). For example, A. 352

*baumannii* was found to be the most competitive bacteria in cultivation, which may be due to its fastest growth rate. On the other hand, *P. aeruginosa* seemed to be relatively the weakest one among them, which was usually concealed in the cultivation with other species existing (sample A16, B19-3, B21-1, B21-2 after we excluded all samples with *A. baumannii* existing).

When evaluating the clinical benefit from SSBD, the quicker directed therapy 358 adjustment for patients in the experiment group (Exp: 10.2±8.8 hours vs. Con: 359 96.0±35.1 hours, p<0.0001, Mann-Whitney test) could shorten the empirical anti-360 361 infection time and seemed to alleviate illness severity (APACHE II score) during the validation stage II with the help of the SSBD. Some clinical parameters were also 362 showed good tendency in the experiment group patients on day 7, including the absolute 363 364 value of white blood cell (WBC), the cases number with abnormal body temperature improved, and the clinical anti-infection efficiency (S6 Table). It implied that 365 appropriate antibiotic treatment guided by in-time pathogenic information would 366 alleviate acute physiological illness. Nevertheless, at the endpoint, clinical outcomes 367 showed no differences between the two groups, which may due to the insufficient 368 patient numbers. 369

Despite the size in our intervention stage, there were still some aspects that have not been considered. 1) Resistance genes were not included in the study. Multi-drug resistant organisms (MDROs) prevailed in ICU [24, 25], which might not improve the situation of patients even with accurate pathogenic information. There were a few cases (e.g. B07, B25 and B35 patients) showing no signs of clearing the bacterial infection.

2) The 10 designed pathogens were originated from sepsis, which might not completely overlap with pathogens of severe pneumonia, though pneumonia is one of the most common causes of sepsis. The panel pathogens could be optimized flexibly for meeting diverse clinical needs in the ICU. 3) Other potential pathogenic microbes, such as viruses and fungus, might affect the clinical outcomes considering the complexity of ICU patients.

Previous studies showed that polymicrobial pneumonia is related to an increased risk 381 of inappropriate antimicrobial treatment [26]. In both phases, a total of 55 samples were 382 383 identified as polymicrobial infections by SSBD, while only 14 samples were identified as polymicrobial infections by CCT, which suggested that SSBD could provide more 384 precise pathogenic bacteria information than CCT, especially for those patients with 385 386 polymicrobial infections. On the other hand, nosocomial infections contribute to a considerable proportion of deaths in ICU patients with severe pneumonia [23]. 387 Although SSBD identified similar ratio of nosocomial infection events with CCT (Fig 388 389 **5G**), SSBD provided more timely information for clinical control and response, which might improve the clinical medication decision in ICU. 390

As anticipated, SSBD performed well with high sensitivity and specificity in rapid pathogens identification, and it reduced TTAT, which was associated with more rapid administration of appropriate antimicrobial therapy in the experiment cases. SSBD also has enormous potential in expanding pathogens from different diseases with much more pathogen genomes concluded. We believe that SSBD is competent in the role of clinical application and able to be applied in more clinical research.

#### 397

#### References 398

- 399 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The 400 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama-401 Journal of the American Medical Association. 2016;315(8):801-10.
- 402 2. Ferrer R, Martinez ML, Goma G, Suarez D, Alvarez-Rocha L, de la Torre MV, et al. Improved 403 empirical antibiotic treatment of sepsis after an educational intervention: the ABISS-404 Edusepsis study. Crit Care. 2018;22(1):167.
- 405 3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension 406 before initiation of effective antimicrobial therapy is the critical determinant of survival in 407 human septic shock. Critical Care Medicine. 2006;34(6):1589-96.
- 408 Pulia M, Redwood R. Empiric Antibiotic Prescribing for Suspected Sepsis: A Stewardship 4. 409 Balancing Act. Am J Med Sci. 2020;360(6):613-4.
- 410 Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to 5. 411 Treatment and Mortality during Mandated Emergency Care for Sepsis. New England 412 Journal of Medicine. 2017;376(23):2235-44.
- 413 6. Abd El-Aziz NK, Gharib AA, Mohamed EAA, Hussein AH. Real-time PCR versus MALDI-414 TOF MS and culture-based techniques for diagnosis of bloodstream and pyogenic 415 infections in humans and animals. J Appl Microbiol. 2021;130(5):1630-44.
- 416 Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, et al. Epidemiology and Outcome of Severe 7. 417 Sepsis and Septic Shock in Intensive Care Units in Mainland China. Plos One. 2014;9(9).
- 418 8. Chen H, Yin Y, Gao H, Guo Y, Dong Z, Wang X, et al. Clinical Utility of In-house 419 Metagenomic Next-generation Sequencing for the Diagnosis of Lower Respiratory Tract 420 Infections and Analysis of the Host Immune Response. Clinical Infectious Diseases. 421 2020;71:S416-S26.
- 422 9. Wang S, Ai J, Cui P, Zhu Y, Wu H, Zhang W. Diagnostic value and clinical application of 423 next-generation sequencing for infections in immunosuppressed patients with 424 corticosteroid therapy. Annals of Translational Medicine. 2020;8(5).
- 425 10. Edin A, Eilers H, Allard A. Evaluation of the Biofire Filmarray Pneumonia panel plus for 426 lower respiratory tract infections. Infectious Diseases. 2020;52(7):479-88.
- 427 Jamal W, Al Roomi E, AbdulAziz LR, Rotimi VO. Evaluation of Curetis Unyvero, a Multiplex 11. 428 PCR-Based Testing System, for Rapid Detection of Bacteria and Antibiotic Resistance and 429 Impact of the Assay on Management of Severe Nosocomial Pneumonia. Journal of Clinical 430 Microbiology. 2014;52(7):2487-92.
- 431 12. Trotter AJ, Aydin A, Strinden MJ, O'Grady J. Recent and emerging technologies for the 432 rapid diagnosis of infection and antimicrobial resistance. Current Opinion in Microbiology. 433 2019;51:39-45.
- 434 Nina Dombrowski, Tom A. Williams, Jiarui Sun, Benjamin J. Woodcroft, Jun-Hoe Lee, 13. 435 Bui Quang Minh, Christian Rinke & Anja Spang. Undinarchaeota illuminate DPANN 436 phylogeny and the impact of gene transfer on archaeal evolution. Nature Communication. 437 2020. 11:3939.
- 438 14. Ilana Lauren Brito. Examining horizontal gene transfer in microbial communities. Nature

| 439 |     | Reviews Microbiology. 2021; 19(7): 442-453.  |
|-----|-----|--|
| 440 | 15. | Mathieu Groussin, Mathilde Poyet, Elevated rates of horizontal gene transfer in the              |
| 441 | 10. | industrialized human microbiome. Cell. 2021; 184: 2053–2067.                                     |
| 442 | 16. | C. Maslunka, V. Gurtler and R.J. Seviour. The impact of horizontal gene transfer on              |
| 443 |     | targeting the internal transcribed spacer region (ITS) to identify Acinetobacter junii strains.  |
| 444 |     | Journal of Applied Microbiology. 2015; 118: 1435-1443.   |
| 445 | 17. | José M. Padial and Ignacio De la Riva. A paradigm shift in our view of species drives current    |
| 446 |     | trends in biological classification. Biol. Rev. 2021; 96:731-751.                                |
| 447 | 18. | De Pascale G, Bello G, Tumbarello M, Antonelli M: Severe pneumonia in intensive care:            |
| 448 |     | cause, diagnosis, treatment and management: a review of the literature. <i>Current Opinion</i>   |
| 449 |     | <i>in Pulmonary Medicine</i> 2012, 18(3):213-221.  |
| 450 | 19. | Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-              |
| 451 |     | Loeches I, Leone M, Lupu M-N, Vincent J-L <i>et al</i> . Sepsis in Intensive Care Unit Patients: |
| 452 |     | Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infectious                 |
| 453 |     | <i>Diseases</i> 2018, 5(12).   |
| 454 | 20. | Janice S. Chen, Enbo Ma, Lucas B. Harrington, Maria Da Costa, Xinran Tian, Joel M. Palefsky,     |
| 455 |     | Jennifer A. Doudna. CRISPR-Cas12a target binding unleashes indiscriminate single-                |
| 456 |     | stranded DNase activity. Science. 2018;360:436-439.  |
| 457 | 21. | Jonathan S. Gootenberg, Omar O. Abudayyeh, Max J. Kellner, Julia Joung, James J. Collins,        |
| 458 |     | Feng Zhang. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a,         |
| 459 |     | and Csm6. Science. 2018;360:439-444.   |
| 460 | 22. | Andreia S. Azevedo, Carina Almeida, Luís F. Melo & Nuno F. Azevedo. Impact of                    |
| 461 |     | polymicrobial biofilms in catheterassociated urinary tract infections. Crit Rev Microbiol.       |
| 462 |     | 2016. 43(4):423-439.   |
| 463 | 23. | Rafael Zaragoza, Pablo Vidal-Cortés, Gerardo Aguilar, Marcio Borges, Emili Diaz, Ricard          |
| 464 |     | Ferrer, Emilio Maseda, Mercedes Nieto, Francisco Xavier Nuvials, Paula Ramirez, Alejandro        |
| 465 |     | Rodriguez, Cruz Soriano, Javier Veganzones and Ignacio Martín-Loeches. Update of the             |
| 466 |     | treatment of nosocomial pneumonia in the ICU. 2020. 24(1):383.                                   |
| 467 | 24. | Liu J, Zhang L, Pan J, Huang M, Li Y, Zhang H, et al. Risk Factors and Molecular                 |
| 468 |     | Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant                 |
| 469 |     | Enterobacteriaceae: A Multicenter Study in China. J Infect Dis. 2020;221(Suppl 2):S156-          |
| 470 |     | S63.   |
| 471 | 25. | Yang Q, Zhang H, Yu Y, Kong H, Duan Q, Wang Y, et al. In Vitro Activity of                       |
| 472 |     | Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-                     |
| 473 |     | abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring        |
| 474 |     | Antimicrobial Resistance Trends (SMART), 2015-2018. Clin Infect Dis. 2020;71(Suppl               |
| 475 |     | 4):S427-S35.   |
| 476 | 26. | Lisa Karner, Susanne Drechsler, Magdalena Metzger, Ara Hacobian, Barbara Schädl, Paul            |
| 477 |     | Slezak, Johannes Grillari and Peter Dungel. Antimicrobial photodynamic therapy fighting          |
| 478 |     | polymicrobial infections – a journey from in vitro to in vivo. Photochemical $\&$                |
| 479 |     | Photobiological Sciences. 2020. 19(10):1332-1343.  |
| 480 | 27. | Carolyn B Ibberson and Marvin Whiteley. The social life of microbes in chronic infection.        |
| 481 |     | Current Opinion in Microbiology. 2020. 53:44-50.   |
| 482 |     |  |
| 102 |     |  |

483

| 484 | <b>Figure</b> | Legends |
|-----|---------------|---------|
|     |               |         |

485

#### 486 Figure 1: Study Design

- 487 This study contained four stages: discovery stage, training stage, validation stage I and
- 488 validation stage II. All patients were from the Department of Critical Care Medicine,
- 489 Nanjing Drum Tower Hospital. Patients were randomly divided into two groups for the
- 490 clinical trial.
- 491

#### 492 Figure 2: Screening workflow and statistics of species-specific DNA-tags.

493 A. Schematic diagram of screening species-specific DNA-tags.

494 B. Genomic distribution of species-specific DNA-tags in 10 bacteria.

- 495 C. Genomic proportion of species-specific DNA-tags in 10 bacteria.
- 496

#### 497 Figure 3: SSBD development and effectiveness validation.

498 A. SSBD workflow for clinical validation stages.

499 B. Cas12a and Cas12a-after-PCR detection of different concentrations and reaction

times including 30 minutes (left) and 60 minutes (right). Blue bars indicated the


- 501 Cas12a-after-PCR test. Brown bars indicated Cas12a test only. The concentration
- gradient of pGL3 plasmid from  $10^{-17}$  M- $10^{-7}$ M was established as the test group.
- 503 NC stood for the fluorescence values of PCR products of using DEPC-H2O as input.
- Each group had three repeats. Error bars indicated mean±SEM of fluorescence
- value. \*\* indicated p value<0.01 and \*\*\* indicated p value<0.001 of unpaired t-test.
- 506 C. SSBD results of 10 pathogenic bacteria.

| 507 | Every test panel for each of 10 bacteria was used to detect genome DNA samples of 10    |
|-----|---|
| 508 | bacteria by SSBD. NC stood for the fluorescence values of PCR products of using         |
| 509 | DEPC-H2O as input. Each group had three repeats. Error bars indicated mean±SEM          |
| 510 | of fluorescence value.  |
| 511 |   |
| 512 | Figure 4: Statistical analysis of test results and clinical outcomes in the two         |
| 513 | validation stages.  |
| 514 | A. Cross-tables for 5 of 10 bacteria by both SSBD and CCT and comparative analysis      |
| 515 | of SSBD, CCT and NGS results in the validation stage I.                                 |
| 516 | B. Cross-tables for 5 of 10 bacteria by both SSBD and CCT and comparative analysis      |
| 517 | of SSBD, CCT and NGS results in the validation stage II.                                |
| 518 | C. Antibiotics coverage rate of each test in the two groups. Exp meant the experimental |
| 519 | group, and Con meant the control group. Test 1: Day 1. Test 2: Day 3-5. Test 3: Day 7+. |
| 520 | Raw antibiotics coverage results of each patient were available in S2B Fig. Detailed    |
| 521 | judging guidelines were shown in Supplementary Material.                                |
| 522 | D and E. Line charts for APACHE II and SOFA scores, respectively. Error bars            |
| 523 | indicated mean±SEM of scores of all the recorded patients. * indicated a significant    |
| 524 | difference between the two groups using two-way ANOVA.                                  |
| 525 |   |
| 526 | Figure 5: Statistical analysis of polymicrobial infection and nosocomial infection      |
| 527 | in the two validation stages.   |
|     |   |

528 A. Statistics of pathogenic infection status of BALF samples in the two validation

- 529 stages.
- 530 B. Verification from NGS results for 6 samples identified as polymicrobial infection by
- 531 SSBD but not CCT.
- 532 C. Case study of polymicrobial infection detected by SSBD and CCT.
- 533 D. Statistics of pathogens involved in polymicrobial infections in the two stages.
- 534 E. Case study of nosocomial infection identified by SSBD.
- 535 F. Case study of nosocomial infection identified by CCT.
- 536 G. Percentage of nosocomial infection identified by SSBD and CCT.


537




perpetuity. All rights reserved. No reuse allowed without permission.

## Fig 2

### Α





сст

Negative

7

62

Specificity

. 89.9%

Negative

9

65

Specificity 87.8%

S. maltophilia

K. pneumoniae

сст

Positive

8

0

Sensitivity

100%

Positive

3

0

Sensitivity 100%

Positive

Negative

Positive

Negative

SSBD

Predictive

Value

PPV

53.3%

NPV

100%

77

Predictive

Value

PPV

25.0%


NPV


100%

77


### Fig 4


### A Validation Stage I






### **B** Validation Stage II










|               | сст      |                     |                      |                     |  |
|---------------|----------|---------------------|----------------------|---------------------|--|
|               |          | Positive            | Negative             | Predictive<br>Value |  |
| SSBD          | Positive | 4                   | 2                    | PPV<br>66.7%        |  |
|               | Negative | 0                   | 37                   | NPV<br>100%         |  |
|               |          | Sensitivity<br>100% | Specificity<br>94.9% | 43                  |  |
| K. pneumoniae |          |                     |                      |                     |  |

#### сст Predictive Positive Negative Value PPV Positive 6 7 46.2% SSBD NPV Negative 0 30 100% Sensitivity 100% Specificity 81.1% 43 S. maltophilia










|           | сст      |                     |                      |                     |
|-----------|----------|---------------------|----------------------|---------------------|
| SSBD      |          | Positive            | Negative             | Predictive<br>Value |
|           | Positive | 1                   | 3                    | PPV<br>25.0%        |
|           | Negative | 0                   | 39                   | NPV<br>100%         |
|           |          | Sensitivity<br>100% | Specificity<br>92.9% | 43                  |
| S. aureus |          |                     |                      |                     |



Е









Fig 5













## **Supplementary Figure 5**

## A Validation stage I





### **B** Validation stage II

